OhioHealth hospital was the first to use the FDA Approved Drug, Ocrevus
…
Categories
Latest Blog Posts
- The Midnight Bathroom Run From Hell – a patient’s story
- The Effect of Seasonal Changes on Multiple Sclerosis
- A Case Study in Neurotherapeutic Clinical Trial Design and Conduct
- Let’s Move From Categorizing MS by Clinical Phenotype to Underlying Disease Mechanisms
- Could Serum Neurofilament Light (sNFL) Chain Level Help Guide MS Management?
- When Multiple Sclerosis Is Suspected in Patients Under 18 or Over 50
- First Evidence of Delayed Disability Progression in Non-relapsing Secondary Progressive Multiple Sclerosis (nrSPMS)
- Factors Influencing Time Delays in Initiating High-Efficacy Treatment in Multiple Sclerosis: Valentin Krüger, MD
- New Novartis data in relapsing MS reinforce benefits of Kesimpta® for first-line and switch patients
- Insomnia and MS: Expert Approaches to Better Sleep
- Press Release: FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
- Multiple Sclerosis and Mental Health: 3 Common Challenges
- 7 Tips for Talking with Friends and Family About Your Chronic Illness
- Battling the Dark Clouds of Depression When Living with MS
- The Ultimate Guide to MS for the Newly Diagnosed
- Cell-based therapeutic strategies for multiple sclerosis
- What to Know About Neuropathic Pain (and How to Manage It)
- video presentation Defining the “Pathways to Cures Roadmap” with global collaboration
- video: AGING and Multiple Sclerosis
- Re-defined Pathways to Cures Roadmap